Rolf W Sparidans

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4113056/publications.pdf

Version: 2024-02-01

84 papers	2,029 citations	236925 25 h-index	276875 41 g-index
84 all docs	84 docs citations	84 times ranked	2600 citing authors

#	Article	IF	Citations
1	Development and validation of an LC-MS/MS assay for the quantification of cintirorgon (LYC-55716) in mouse plasma and tissue homogenates. Journal of Pharmaceutical and Biomedical Analysis, 2022, 207, 114421.	2.8	1
2	Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinib. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 170, 197-207.	4.3	0
3	A robust, accurate, sensitive LCâ€“MS/MS method to measure indoxyl sulfate, validated for plasma and kidney cells. Biomedical Chromatography, 2022, 36, .	1.7	5
4	ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability. Pharmacological Research, 2022, 178, 106137.	7.1	4
5	Extrahepatic metabolism of ibrutinib. Investigational New Drugs, 2021, 39, 1-14.	2.6	12
6	ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib. Molecular Cancer Therapeutics, 2021, 20, 1173-1182.	4.1	6
7	Bioanalysis of erlotinib, its O-demethylated metabolites OSI-413 and OSI-420, and other metabolites by liquid chromatography-tandem mass spectrometry with additional ion mobility identification. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1166, 122554.	2.3	4
8	MO622IMPAIRED PROTEIN-BOUND UREMIC TOXIN EXCRETION SUGGESTS TUBULAR DYSFUNCTION IN DIABETIC NEPHROPATHY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
9	Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1174, 122718.	2.3	11
10	ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib. Pharmacological Research, 2021, 172, 105850.	7.1	6
11	Chromatographic bioanalytical assays for targeted covalent kinase inhibitors and their metabolites. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1162, 122466.	2.3	6
12	ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability. Pharmaceutics, 2021, 13, 1761.	4.5	6
13	P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO). Pharmaceuticals, 2021, 14, 1087.	3.8	2
14	P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554). International Journal of Pharmaceutics, 2020, 573, 118842.	5.2	10
15	Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1147, 122131.	2.3	8
16	OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation. British Journal of Pharmacology, 2020, 177, 3060-3074.	5.4	14
17	Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1144, 122098.	2.3	7
18	Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 136, 120-130.	4.3	17

#	Article	IF	Citations
19	Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). Pharmacological Research, 2019, 146, 104297.	7.1	29
20	Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1122-1123, 78-82.	2.3	5
21	Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1110-1111, 116-123.	2.3	9
22	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice. International Journal of Pharmaceutics, 2019, 556, 172-180.	5.2	10
23	Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1083, 204-208.	2.3	16
24	Quantification of cystine in human renal proximal tubule cells using liquid chromatographyâ€“tandem mass spectrometry. Biomedical Chromatography, 2018, 32, e4238.	1.7	12
25	Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells. Pharmaceutical Research, 2018, 35, 85.	3.5	22
26	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice. Pharmacological Research, 2018, 129, 414-423.	7.1	31
27	P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability. Pharmacological Research, 2018, 137, 47-55.	7.1	25
28	P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Brutonâ€™s Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability. Molecular Pharmaceutics, 2018, 15, 5124-5134.	4.6	15
29	Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1102-1103, 167-172.	2.3	10
30	Pâ€glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450â€3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib. International Journal of Cancer, 2018, 143, 2029-2038.	5.1	32
31	Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates. Journal of Pharmaceutical and Biomedical Analysis, 2018, 161, 136-143.	2.8	22
32	Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. Pharmacological Research, 2017, 120, 43-50.	7.1	43
33	Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2). Molecular Pharmaceutics, 2017, 14, 3258-3268.	4.6	25
34	Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1061-1062, 300-305.	2.3	7
35	Liquid chromatographyâ€“tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1023-1024, 24-29.	2.3	11
36	Liquid chromatographyâ¿¿tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the Oâ¿¿ desmethyl metabolites of erlotinib and gefitinib in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1033-1034, 390-398.	2.3	30

#	Article	IF	Citations
37	Liquid chromatographyâ€“tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1031, 80-85.	2.3	38
38	Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology. Journal of Pharmaceutical and Biomedical Analysis, 2016, 130, 244-263.	2.8	26
39	Liquid chromatographyâ€“tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquidâ€“liquid extraction. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1012-1013, 118-123.	2.3	18
40	Liquid chromatographyâ€“tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis, 2016, 118, 123-131.	2.8	39
41	Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1). Pharmaceutical Research, 2015, 32, 2205-2216.	3.5	53
42	Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699). Pharmaceutical Research, 2015, 32, 37-46.	3.5	79
43	Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. Clinical Cancer Research, 2015, 21, 5100-5109.	7.0	49
44	Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate. Journal of Pharmaceutical and Biomedical Analysis, 2015, 107, 403-408.	2.8	4
45	Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). Pharmacological Research, 2015, 102, 200-207.	7.1	59
46	Liquid chromatographyâ€“tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma. Biomedical Chromatography, 2014, 28, 1366-1370.	1.7	22
47	Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the Pâ€glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. International Journal of Cancer, 2014, 134, 1484-1494.	5.1	127
48	P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice. Clinical Cancer Research, 2014, 20, 3133-3145.	7.0	29
49	Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma. Journal of Pharmaceutical and Biomedical Analysis, 2014, 92, 144-148.	2.8	2
50	Liquid chromatographyâ€“tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma. Journal of Pharmaceutical and Biomedical Analysis, 2014, 88, 216-220.	2.8	10
51	Liquid chromatographyâ€“tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma. Journal of Pharmaceutical and Biomedical Analysis, 2014, 88, 626-629.	2.8	14
52	Liquid chromatographyâ€“tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 925, 124-128.	2.3	12
53	Liquid chromatographyâ€“tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 934, 22-25.	2.3	10
54	Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Gene Dosage on Plasma Pharmacokinetics and Brain Accumulation of Dasatinib, Sorafenib, and Sunitinib. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 486-494.	2.5	48

#	Article	IF	Citations
55	The potency of clobetasol propionate: Serum levels of clobetasol propionate and adrenal function during therapy with 0.05% clobetasol propionate in patients with severe atopic dermatitis. Journal of Dermatological Treatment, 2012, 23, 16-20.	2.2	13
56	Oral Availability and Brain Penetration of the B-RAF^{V600E} Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar. Molecular Pharmaceutics, 2012, 9, 3236-3245.	4.6	113
57	Organic Anion-Transporting Polypeptides 1a/1b Control the Hepatic Uptake of Pravastatin in Mice. Molecular Pharmaceutics, 2012, 9, 2497-2504.	4.6	24
58	Liquid chromatographyâ€“tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 889-890, 144-147.	2.3	14
59	Liquid chromatographyâ€“tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 905, 137-140.	2.3	15
60	Liquid chromatographyâ€“tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 905, 150-154.	2.3	23
61	Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells. International Journal of Nanomedicine, 2012, 7, 417.	6.7	22
62	Liquid chromatographyâ€“tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N+-glucuronide in plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 895-896, 169-173.	2.3	2
63	Liquid chromatographyâ€“tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 895-896, 174-177.	2.3	9
64	Dendrimerâ€Based Macromolecular Conjugate for the Kidneyâ€Directed Delivery of a Multitargeted Sunitinib Analogue. Macromolecular Bioscience, 2012, 12, 93-103.	4.1	17
65	Liquid chromatographyâ€“tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 1851-1856.	2.3	29
66	Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics. Drug Metabolism and Disposition, 2011, 39, 729-735.	3.3	62
67	Liquid chromatographyâ€“tandem mass spectrometric assay for clobetasol propionate in human serum from patients with atopic dermatitis. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 2150-2154.	2.3	6
68	Liquid chromatographic assay with fluorescence detection to determine ajmaline in serum from patients with suspected Brugada syndrome. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 2168-2172.	2.3	1
69	Liquid chromatography-tandem mass spectrometric assay for pravastatin and two isomeric metabolites in mouse plasma and tissue homogenates. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 2751-2759.	2.3	11
70	Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation. Molecular Cancer Therapeutics, 2010, 9, 319-326.	4.1	171
71	Hepatic Clearance of Reactive Glucuronide Metabolites of Diclofenac in the Mouse Is Dependent on Multiple ATP-Binding Cassette Efflux Transporters. Molecular Pharmacology, 2010, 77, 687-694.	2.3	67
72	Liquid chromatographyâ€“tandem mass spectrometric assay for sorafenib and sorafenibâ€“glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 269-276.	2.3	31

#	Article	IF	Citations
73	Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 4090-4096.	2.3	43
74	Liquid chromatographyâ€“tandem mass spectrometric assay for diclofenac and three primary metabolites in mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 872, 77-82.	2.3	63
75	Liquid chromatographyâ€“tandem mass spectrometric assay for the nucleoside reverse transcriptase inhibitor emtricitabine in human plasma. Biomedical Chromatography, 2007, 21, 621-627.	1.7	14
76	Liquid chromatographyâ€“tandem mass spectrometric assays for salinomycin in mouse plasma, liver, brain and small intestinal contents and in OptiMEM cell culture medium. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 855, 200-210.	2.3	13
77	Liquid chromatographyâ€“tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and Î²-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 839, 45-53.	2.3	25
78	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (YondelisÂ®, TrabectidinÂ®), a novel marine anti-cancer drug. Investigational New Drugs, 2006, 24, 3-14.	2.6	36
79	Liquid chromatographic assay for the protease inhibitor atazanavir in plasma. Biomedical Chromatography, 2006, 20, 72-76.	1.7	17
80	Liquid chromatographic assay for the non-peptidic protease inhibitor tipranavir in plasma. Biomedical Chromatography, 2006, 20, 671-673.	1.7	1
81	Liquid chromatographic assay for the cyclic depsipeptide aplidine, a new marine antitumor drug, in whole blood using derivatization withtrans-4â€²-hydrazino-2-stilbazole. Biomedical Chromatography, 2004, 18, 16-20.	1.7	7
82	Simple high-performance liquid chromatographic assay for melphalan in perfusate, rat liver and tumour tissue. Biomedical Chromatography, 2003, 17, 458-464.	1.7	11
83	Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 791, 227-233.	2.3	40
84	Isocratic ion-exchange chromatographic assay for the nucleotide gemcitabine triphosphate in human white blood cells. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 780, 423-430.	2.3	17